PT1230347E - Método de preparação de rna do hcv purificado por separação de exossomas - Google Patents
Método de preparação de rna do hcv purificado por separação de exossomas Download PDFInfo
- Publication number
- PT1230347E PT1230347E PT00979837T PT00979837T PT1230347E PT 1230347 E PT1230347 E PT 1230347E PT 00979837 T PT00979837 T PT 00979837T PT 00979837 T PT00979837 T PT 00979837T PT 1230347 E PT1230347 E PT 1230347E
- Authority
- PT
- Portugal
- Prior art keywords
- hcv
- exosome
- particles
- preparation
- rna
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 28
- 238000000926 separation method Methods 0.000 title abstract description 9
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 59
- 239000002245 particle Substances 0.000 claims abstract description 36
- 210000002381 plasma Anatomy 0.000 claims abstract description 23
- 238000000605 extraction Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 25
- 239000011324 bead Substances 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 13
- 238000001085 differential centrifugation Methods 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000012228 culture supernatant Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 101710165845 CD81 protein Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000002955 isolation Methods 0.000 abstract description 5
- 239000008188 pellet Substances 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 238000001262 western blot Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 102100027221 CD81 antigen Human genes 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 2
- 101710125507 Integrase/recombinase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000013378 biophysical characterization Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 102000055772 human CD81 Human genes 0.000 description 1
- 102000045407 human CD82 Human genes 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24251—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9927320.3A GB9927320D0 (en) | 1999-11-18 | 1999-11-18 | Exosome separation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1230347E true PT1230347E (pt) | 2007-12-20 |
Family
ID=10864765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT00979837T PT1230347E (pt) | 1999-11-18 | 2000-11-20 | Método de preparação de rna do hcv purificado por separação de exossomas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7198923B1 (OSRAM) |
| EP (1) | EP1230347B1 (OSRAM) |
| JP (1) | JP4675017B2 (OSRAM) |
| AT (1) | ATE373084T1 (OSRAM) |
| AU (1) | AU1721801A (OSRAM) |
| CA (1) | CA2392075C (OSRAM) |
| CY (1) | CY1107521T1 (OSRAM) |
| DE (1) | DE60036403T2 (OSRAM) |
| DK (1) | DK1230347T3 (OSRAM) |
| ES (1) | ES2292489T3 (OSRAM) |
| GB (1) | GB9927320D0 (OSRAM) |
| PT (1) | PT1230347E (OSRAM) |
| WO (1) | WO2001036601A1 (OSRAM) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9927320D0 (en) * | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
| US8021847B2 (en) | 2004-06-02 | 2011-09-20 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
| US20080268429A1 (en) * | 2004-06-02 | 2008-10-30 | Sourcepharm, Inc. | Rna - Containing Microvesicles and Methods Therefor |
| CA3061952C (en) * | 2006-03-09 | 2022-07-19 | Aethlon Medical, Inc. | Extracorporeal removal of microvesicular particles |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| US8617806B2 (en) * | 2008-01-25 | 2013-12-31 | Hansabiomed Ou | Method to measure and characterize microvesicles in the human body fluids |
| ES2936256T3 (es) * | 2008-02-01 | 2023-03-15 | Massachusetts Gen Hospital | Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas |
| WO2014057128A2 (en) | 2012-10-11 | 2014-04-17 | Vin-De-Bona Trading Company Pte Ltd | Method of painting microvesicles |
| US11266736B2 (en) | 2008-04-17 | 2022-03-08 | Vin De Bona Trading Company Pte Ltd | Method of painting micro vesicles |
| AU2009259893A1 (en) * | 2008-06-20 | 2009-12-23 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
| US9487837B2 (en) | 2008-10-06 | 2016-11-08 | Morehouse School Of Medicine | Exosome-mediated diagnosis of hepatitis virus infections and diseases |
| US10545149B2 (en) * | 2008-10-06 | 2020-01-28 | Morehouse School Of Medicine | Detection of HIV-related proteins in urine |
| CN102308004A (zh) | 2008-10-30 | 2012-01-04 | 卡里斯生命科学卢森堡控股有限责任公司 | 评价rna图案的方法 |
| CA2743211A1 (en) | 2008-11-12 | 2010-05-20 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods and systems of using exosomes for determining phenotypes |
| EP2419144B1 (en) | 2009-04-17 | 2019-08-07 | Oxford University Innovation Limited | Composition for delivery of genetic material |
| BRPI0900815A2 (pt) * | 2009-04-23 | 2010-12-28 | Sociedade Benef Israelita Bras Hospital Albert Einstein | método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro |
| IN2012DN00866A (OSRAM) | 2009-07-16 | 2015-07-10 | Gen Hospital Corp | |
| WO2011031892A1 (en) | 2009-09-09 | 2011-03-17 | The General Hospital Corporation | Use of microvesicles in analyzing kras mutations |
| WO2011031877A1 (en) | 2009-09-09 | 2011-03-17 | The General Hospital Corporation | Use of microvesicles in analyzing nucleic acid profiles |
| WO2011049059A1 (ja) * | 2009-10-22 | 2011-04-28 | 国立大学法人岐阜大学 | Ｒｎａ内包キャリア組成物 |
| US20130203061A1 (en) | 2009-11-30 | 2013-08-08 | Michael KLASS | Methods and systems for isolating, storing, and analyzing vesicles |
| US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| WO2011156734A2 (en) * | 2010-06-11 | 2011-12-15 | Hitachi Chemical Co., Ltd. | Method of characterizing vascular diseases |
| WO2011156763A1 (en) | 2010-06-11 | 2011-12-15 | Hitachi Chemical Co., Ltd. | Methods for characterizing kidney function |
| EP2591359B1 (en) | 2010-07-07 | 2017-03-01 | Aethlon Medical Inc | Methods for quantifying exosomes |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| EP2638057B1 (en) | 2010-11-10 | 2019-03-06 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| ES2744589T3 (es) | 2011-05-11 | 2020-02-25 | Exosome Diagnostics Inc | Extracción de ácido nucleico de materiales biológicos heterogéneos |
| JP5823031B2 (ja) | 2011-06-10 | 2015-11-25 | 日立化成株式会社 | 小胞捕捉デバイスおよびそれを用いるための方法 |
| EP2723865B1 (en) | 2011-06-21 | 2019-03-27 | Alnylam Pharmaceuticals, Inc. | METHODS FOR DETERMINING ACTIVITY OF RNAi IN A SUBJECT |
| WO2013028788A1 (en) | 2011-08-22 | 2013-02-28 | Exosome Diagnostics, Inc. | Urine biomarkers |
| HK1199754A1 (en) * | 2011-09-22 | 2015-07-17 | Universidad De Los Andes | Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage |
| US10174361B2 (en) | 2011-11-10 | 2019-01-08 | Exosome Diagnostics, Inc. | Cerebrospinal fluid assay |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| EP2875348B1 (en) * | 2012-07-19 | 2018-09-26 | Atlantic Cancer Research Institute | Method for the isolation of microvesicles |
| EP2890783A4 (en) | 2012-08-30 | 2016-03-02 | Exosome Diagnostics Inc | WITNESSES FOR NUCLEIC ACID ASSAYS |
| CN105025878A (zh) | 2012-10-03 | 2015-11-04 | 外来体诊断公司 | 微泡在医学疾病和病况的诊断、预后和治疗中的用途 |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| US20150353920A1 (en) | 2013-01-03 | 2015-12-10 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles |
| US12558316B2 (en) | 2013-03-13 | 2026-02-24 | University Of Miami | Methods and compositions for the treatment of epidermolysis bullosa |
| CA2906502A1 (en) | 2013-03-13 | 2014-10-02 | University Of Miami | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids |
| JP6297676B2 (ja) | 2013-05-06 | 2018-03-20 | 日立化成株式会社 | 標的分子を捕捉するためのデバイス及び方法 |
| US10301681B2 (en) | 2013-08-06 | 2019-05-28 | Exosome Diagnostics, Inc. | Methods of treating a subject with a high gleason score prostate cancer |
| WO2015031694A2 (en) | 2013-08-28 | 2015-03-05 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| TWI788704B (zh) * | 2013-10-24 | 2023-01-01 | 美商納諾索米克斯公司 | 分析個體樣品之方法 |
| WO2015112382A1 (en) * | 2014-01-21 | 2015-07-30 | Morehouse School Of Medicine | Exosome-mediated detection of infections and diseases |
| US10844436B2 (en) | 2014-04-01 | 2020-11-24 | Cornell University | Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection |
| US11268085B2 (en) | 2014-05-27 | 2022-03-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| US10465183B2 (en) | 2014-07-09 | 2019-11-05 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| EP3808756A1 (en) | 2014-07-17 | 2021-04-21 | The Trustees of The University of Pennsylvania | Methods for using exosomes to monitor transplanted organ status |
| US10266895B2 (en) | 2014-11-05 | 2019-04-23 | Hitachi Chemical Company Ltd. | Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease |
| US10370719B2 (en) | 2014-11-12 | 2019-08-06 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
| EP3112474A1 (en) | 2015-06-29 | 2017-01-04 | Evonik Degussa GmbH | Method of detecting avian necrotic enteritis |
| AU2016229076B2 (en) | 2015-03-09 | 2022-01-20 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| IL256175B2 (en) | 2015-06-10 | 2024-10-01 | Univ Texas | Using exosomes to treat the disease |
| IL318703A (en) | 2015-06-29 | 2025-03-01 | Caris Science Inc | Therapeutic oligonucleotides |
| EP3328873B1 (en) | 2015-07-28 | 2025-09-17 | Caris Science, Inc. | Targeted oligonucleotides |
| JP6624704B2 (ja) | 2015-08-31 | 2019-12-25 | 日立化成株式会社 | 尿路上皮疾患の評価のための分子法 |
| EP3165926A1 (en) | 2015-11-06 | 2017-05-10 | Humanitas Mirasole S.p.A. | Method for characterization of cell specific microvesicles |
| WO2017181161A1 (en) | 2016-04-15 | 2017-10-19 | Predicine, Inc. | Systems and methods for detecting genetic alterations |
| US20190093172A1 (en) | 2016-04-15 | 2019-03-28 | Exosome Diagnostics, Inc. | Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer |
| EP4299803A3 (en) | 2016-05-02 | 2024-03-27 | Encodia, Inc. | Macromolecule analysis employing nucleic acid encoding |
| EP3452613B1 (en) | 2016-05-05 | 2021-12-29 | Exosome Diagnostics, Inc. | Profiling microvesicle nucleic acids and uses thereof as signatures in diagnosis of renal transplant rejection |
| CN109642229A (zh) | 2016-05-13 | 2019-04-16 | 外来体诊断公司 | 从生物液体分离细胞外囊泡和共分离无细胞dna的自动和手动方法 |
| IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
| US11174503B2 (en) | 2016-09-21 | 2021-11-16 | Predicine, Inc. | Systems and methods for combined detection of genetic alterations |
| WO2018055080A1 (en) | 2016-09-22 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof |
| US11396676B2 (en) | 2016-10-21 | 2022-07-26 | Exosome Diagnostics, Inc. | Sequencing and analysis of exosome associated nucleic acids |
| EP3548635B1 (en) | 2016-11-30 | 2021-04-28 | Exosome Diagnostics, Inc. | Methods to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients |
| GB2559319B (en) | 2016-12-23 | 2019-01-16 | Cs Genetics Ltd | Reagents and methods for the analysis of linked nucleic acids |
| US20200149036A1 (en) | 2017-01-02 | 2020-05-14 | Exosome Diagnostics, Inc. | Methods to distinguish rna and dna in a combined preparation |
| BR112019023772A2 (pt) | 2017-05-12 | 2020-06-09 | Evonik Operations Gmbh | método para detectar doenças induzidas por c. perfringens em animais e kit de diagnóstico |
| JP7225121B2 (ja) | 2017-05-17 | 2023-02-20 | エクソサム ダイアグノスティクス，インコーポレイティド | 微小胞核酸および／またはタンパク質、並びに腎移植拒絶反応マーカーとしてのその使用 |
| EP3652315A4 (en) * | 2017-07-12 | 2021-09-01 | Exosome Diagnostics, Inc. | METHODS FOR ISOLATION AND ENRICHMENT OF EXTRACELLULAR VESICLE POPULATIONS DERIVED FROM BIOFLUIDS, AND ASSOCIATED METHODS OF USE |
| EP3655531B1 (en) | 2017-07-18 | 2024-09-04 | Exosome Diagnostics, Inc. | Sequencing of nucleic acids associated with exosomal isolation from patients with glioblastoma multiforme |
| AU2018358057B2 (en) | 2017-10-31 | 2023-03-02 | Encodia, Inc. | Kits for analysis using nucleic acid encoding and/or label |
| US20200339987A1 (en) | 2017-11-09 | 2020-10-29 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining expression of the lect2 gene |
| CN110123838B (zh) * | 2018-02-02 | 2022-04-01 | 上海睿泰生物科技股份有限公司 | 负载白藜芦醇的人多能干细胞外泌体及其制备方法与用途 |
| CN110123841A (zh) * | 2018-02-09 | 2019-08-16 | 上海市第六人民医院 | 负载白藜芦醇的人多能干细胞外泌体在制备治疗生殖系统疾病药物的用途 |
| US20210011027A1 (en) | 2018-03-02 | 2021-01-14 | Evonik Operations Gmbh | In vitro method for detecting intestinal barrier failure in animals by determining ovotransferrin |
| CN112739832B (zh) | 2018-06-06 | 2024-06-04 | 外来体诊断公司 | 用于开发尿液生物标志物和用于检测膀胱癌的方法 |
| WO2020106853A1 (en) | 2018-11-20 | 2020-05-28 | Exosome Diagnostics, Inc. | Compositions and methods for internal controls of microvesicle isolations |
| MX2021006917A (es) | 2018-12-14 | 2021-07-07 | Evonik Operations Gmbh | Procedimiento in vitro para la deteccion de disbiosis intestinal aviar. |
| CN114072499B (zh) | 2019-04-30 | 2024-08-06 | Encodia公司 | 用于制备分析物的方法和相关试剂盒 |
| EP4031865A2 (en) * | 2019-09-18 | 2022-07-27 | Exosome Diagnostics, Inc. | Compositions, methods, and kits for the isolation of extracellular vesicles |
| CN115666619A (zh) | 2020-04-13 | 2023-01-31 | 埃索普罗瑟医疗有限公司 | 用于抗病毒治疗的包含野生型p53蛋白的细胞衍生囊泡 |
| US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | A method for diagnosing breast cancer |
| TW202214851A (zh) * | 2020-10-07 | 2022-04-16 | 國立中央大學 | 外泌體核酸萃取方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225068B1 (en) * | 1989-03-17 | 2006-05-29 | Chiron Corp | Process for producing diagnostics and vaccine of nanbh |
| US5372928A (en) * | 1989-09-15 | 1994-12-13 | Chiron Corporation | Hepatitis C virus isolates |
| AU7672991A (en) * | 1990-04-03 | 1991-10-30 | Southwest Foundation For Biomedical Research | Purified hcv and hcv proteins and peptides |
| GB9416671D0 (en) | 1994-08-17 | 1994-10-12 | Biocine Spa | Assay |
| CA2225553A1 (en) * | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| GB9517926D0 (en) | 1995-09-01 | 1995-11-01 | Biocine Spa | Binding protein |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| ATE449847T1 (de) | 1997-10-06 | 2009-12-15 | Novartis Vaccines & Diagnostic | Hepatitis c rezeptorprotein cd81 |
| AU756303B2 (en) | 1997-11-06 | 2003-01-09 | Innogenetics N.V. | Host derived proteins binding HCV: medical, diagnostic and purification use |
| GB9927320D0 (en) * | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
-
1999
- 1999-11-18 GB GBGB9927320.3A patent/GB9927320D0/en not_active Ceased
-
2000
- 2000-11-20 JP JP2001538480A patent/JP4675017B2/ja not_active Expired - Fee Related
- 2000-11-20 DK DK00979837T patent/DK1230347T3/da active
- 2000-11-20 ES ES00979837T patent/ES2292489T3/es not_active Expired - Lifetime
- 2000-11-20 US US10/130,467 patent/US7198923B1/en not_active Expired - Lifetime
- 2000-11-20 AT AT00979837T patent/ATE373084T1/de active
- 2000-11-20 EP EP00979837A patent/EP1230347B1/en not_active Expired - Lifetime
- 2000-11-20 DE DE60036403T patent/DE60036403T2/de not_active Expired - Lifetime
- 2000-11-20 CA CA2392075A patent/CA2392075C/en not_active Expired - Lifetime
- 2000-11-20 WO PCT/IB2000/001801 patent/WO2001036601A1/en not_active Ceased
- 2000-11-20 AU AU17218/01A patent/AU1721801A/en not_active Abandoned
- 2000-11-20 PT PT00979837T patent/PT1230347E/pt unknown
-
2007
- 2007-01-30 US US11/699,925 patent/US7807438B2/en not_active Expired - Fee Related
- 2007-12-07 CY CY20071101559T patent/CY1107521T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1230347A1 (en) | 2002-08-14 |
| JP4675017B2 (ja) | 2011-04-20 |
| ES2292489T3 (es) | 2008-03-16 |
| GB9927320D0 (en) | 2000-01-12 |
| ATE373084T1 (de) | 2007-09-15 |
| DK1230347T3 (da) | 2007-11-05 |
| US7807438B2 (en) | 2010-10-05 |
| CA2392075A1 (en) | 2001-05-25 |
| DE60036403T2 (de) | 2008-06-12 |
| WO2001036601A1 (en) | 2001-05-25 |
| JP2003514523A (ja) | 2003-04-22 |
| CA2392075C (en) | 2011-01-04 |
| AU1721801A (en) | 2001-05-30 |
| US7198923B1 (en) | 2007-04-03 |
| US20070254351A1 (en) | 2007-11-01 |
| CY1107521T1 (el) | 2013-03-13 |
| DE60036403D1 (de) | 2007-10-25 |
| EP1230347B1 (en) | 2007-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7807438B2 (en) | Preparation of purified exosomes comprising HCV RNA | |
| AU2008276880B2 (en) | Production and use of epitope-tagged hepatitis C virus particle | |
| JP4231083B2 (ja) | Ｃ型肝炎ウイルス様粒子の合成および精製 | |
| JP2003514523A5 (OSRAM) | ||
| CA2045323C (en) | Non-a, non-b hepatitis virus genomic cdna and antigen polypeptide | |
| JPH04501203A (ja) | 後―輸血性，非―ａ，非―ｂ型肝炎ウィルス及び抗原 | |
| BRPI0011369B1 (pt) | Método de detecção precoce de uma infecção flaviviral, kit de diagnóstico precoce, processo de purificação da protéina ns1 de um flavivírus composição imunogese, utilização da proteína ns1, de pelo menos um anticorpo monoclonal anti-ns1, e, processo de expressão de um polinucleotídeo codificado para a proteína ns1 de um vírus da dengue | |
| HU227498B1 (en) | Process for production of hepatitis c virus asialoglycoproteins | |
| EP0071640B1 (en) | Non-a, non-b hepatitis virus | |
| JPH05508762A (ja) | 精製されたｈｃｖならびにｈｃｖタンパク質およびペプチド | |
| WO2007146197A1 (en) | Methods and reagents for virus isolation and detection | |
| RU2123528C1 (ru) | Способ получения белков hcv, пригодных для использования в вакцине или иммуноанализе, асиалогликопротеин (варианты), композиция для использования в вакцине или в иммуноанализе (варианты), способ очистки асиалогликопротеина и способ понижения содержания или элиминации hcv | |
| JP2681063B2 (ja) | 腎症候性出血熱ウイルス抗原の製造方法、及び該抗原を含有するワクチン並びに腎症候性出血熱診断剤 | |
| ES2386369T3 (es) | Vacunas que comprenden la proteína de núcleo HBC truncado mas adyuvantes basados en saponina | |
| ES2261457T3 (es) | Complejo lipo-virico de particulas, procedimiento de preparacion y aplicaciones. | |
| JP3269642B2 (ja) | 非Ａ非Ｂ型肝炎ウイルス遺伝子ｃＤＮＡおよび抗原ポリペプチド | |
| Hilleman et al. | Infectious hepatitis (hepatitis A) research in nonhuman primates | |
| Al-Ofairy | A Study of Lymphocyte Transformation Capacity and Phagocytosis Activity in Patients with Hepatitis B A Thesis | |
| Maisch et al. | Diagnostic and pathogenic relevance of antimyocardial antibodies and circulating immune complexes in perimyocarditis and congestive cardiomyopathy | |
| Grimley et al. | CHAPTER III FUNCTIONS AND ALTERATIONS OF CELL MEMBRANES DURING ACTIVE VIRUS INFECTION | |
| Lejtenyi | Lymphocyte transformation in vitro in response to the carcinoembryonic antigen of the human digestive system | |
| Shaw | A Kinetic Study of the Inhibition of DNA Synthesis in L-Cells by Reovirustype 3 | |
| JPH04169193A (ja) | 非ａ非ｂ型肝炎ウイルス抗原ポリペプチド、該抗原ポリペプチドをコードするポリヌクレオチド、及びそれらを用いた非ａ非ｂ型肝炎の診断方法 ４ |